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Hasan Al-Dhekri,1 Hamoud Al-Mousa,1 Mouhab Ayas,2 Saleh Al-Muhsen,1,3
Abdulaziz Al-Ghonaium,1 Ghanam Al-Ghanam,1 Bandar Al-Saud,1 Rand Arnaout,1
Amal Al-Seraihy,2 Ali Al-Ahmari,2 Abdullah Al-Jefri,2 Mohammed Al-Mahr,2 Hassan El-Solh2Leukocyte adhesion deficiency type 1 is a rare autosomal recessive immunodeficiency disorder. The severe
phenotype is fatal unless hematopoietic stem cell transplantation (HSCT) is performed. A retrospective
analysis was performed in 11 patients with leukocyte adhesion deficiency type 1 who underwent HSCT
and monitoring over a period of 19 years at our institution. The median age at HSCT was 8.8 months.
Stem cell sources were unmanipulated bone marrow from an HLA-matched related donor in 7 patients,
unrelated umbilical cord blood in 3 patients, and a mismatched related donor in 1 patient. Three patients
underwent a second HSCT. Conditioning was provided with a busulfan- and cyclophosphamide-based
regimen, with anti-thymocyte immunoglobulin added for the cord blood transplant recipients. Graft-
versus-host-disease prophylaxis consisted of cyclosporine A and methotrexate for related donor recipients
(8 patients) and cyclosporine A and prednisone for cord blood transplant recipients (3 patients). The overall
event-free survival rate was 91% with a median follow-up of 94 months (range, 15-223 months). Ten patients
had immune reconstitution and demonstrated sustained engraftment that ranged from 11% to 100% for lym-
phoid lines and from 0% to 100% for myeloid lines. HSCT from a matched related donor or unrelated cord
blood provided excellent outcome, and mixed chimerism appeared satisfactory to prevent recurrent
infections.
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Primary immunodeficiency diseaseINTRODUCTION
Leukocyte adhesion deficiency type 1 (LAD-1) is
a rare autosomal recessive immunodeficiency disorder
caused by defects in the common b2 subunit (CD18) of
the leukocyte integrins imposed by various types of
mutations [1-3]. The aberrant b2 integrin is either
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6/j.bbmt.2010.12.714the a subunits. In severe deficiency, cell surface
expression of the b2 integrin heterodimers is \1%
of normal levels. These patients usually develop
recurrent infections of the skin and lungs, systemic
sepsis, delayed umbilical cord separation, omphalitis,
impaired pus formation, and delayed wound healing
associated with leukocytosis [4-5]. Patients often die
within the first year secondary to infection.
Allogeneic hematopoietic stem cell transplantation
(HSCT) offers the possibility of cure for patents with
LAD-1 [6-8]. However, because LAD-1 is extremely
rare, experience in any particular center is limited. A
previous 2-center study reported the outcome of 14
matched related and haploidentical donor transplants
performed between 1982 and 1993, with a survival
rate of 71% at 12 months to 12 years post-HSCT
[9]. These studies addressed particular difficulties as-
sociated withHSCT for LAD-1, mainly graft rejection
and graft-versus-host-disease (GVHD).
Data from the registries of the European Society
for Immunodeficiencies, European Group for
Blood and Marrow Transplantation, and Center for1245
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show an overall survival rate of 75% in 36 children
with LAD-1 who underwent HSCT [10]. Outcomes
were comparable in matched related donor (MRD)
and unrelated donor HSCTs. Although the number
of successful unrelated umbilical cord blood
(UR-CB) HSCTs for LAD-1 is limited, UR-CB
appears to be a promising option in the absence of an
MRD [11].
Here, we describe the outcome of one of the largest
single-center study of patients with LAD-1who under-
went HSCT from an MRD, UR-CB, or a mismatched
related donor (MMRD).PATIENTS AND METHODS
Patients
Eleven patients with severe LAD-1 underwent
HSCT at King Faisal Specialist Hospital and Research
Center in Riyadh between January 1991 and Decem-
ber 2008. The diagnosis of LAD-1 was confirmed by
flow cytometric analysis demonstrating defective ex-
pression of\1% CD11/CD18 on the surface of lym-
phocytes and granulocytes. This retrospective chart
review with multivariable factors was approved by
the Research Advisory Council at King Faisal Special-
ist Hospital and Research Center. Data obtained
included the patients’ pre-HSCT clinical and immu-
nologic characteristics, HSCT characteristics, and
post-HSCT complications (ie, age at HSCT, donor
characteristics, HLAmatching, conditioning regimen,
stem cell origin, CD341 cell dose, bone marrow ma-
nipulation, engraftment, GVHD, infections, toxicity,
and outcome), and immune reconstitution post-
HSCT at last follow-up. Isolated pathogens were eval-
uated by culture or polymerase chain reaction of the
material obtained by specimen collection or biopsy.
Conditioning Regimen
The conditioning regimen consisted of busulfan
(BU) 1 mg/kg/dose orally every 6 hours for 4 days (to-
tal dose, 16 mg/kg) on days -10 to -7 and cyclophos-
phamide (CY) 50 mg/kg/dose i.v. for 4 days (total
dose, 200 mg/kg) on days -5 to -2. Rabbit anti-thymo-
cyte immunoglobulin (rATG) at 10 mg/kg/dose i.v.
for 4 days (total dose, 40 mg/kg) on days -5 to -2 was
added for UR-CB recipients.
Three patients (2, 5, and 9) required a second
HSCT. The conditioning regimen consisted of BU
and CY for patient 2, and VP-16 (etoposide) at 300
mg/m2/dose  3 doses (900 mg/m2) i.v. on days -5 to
-2 and rATG with a total dose of 40 mg/kg in addition
to BU and CY for patient 5. In contrast, patient 9 re-
ceived total-body irradiation (TBI) in addition to CY
and rATG. Patient 2 underwent T cell depletion
with alemtuzumab (Campath).The grafts were unmanipulated marrow from
HLA-genoidentical siblings in 7 patients, UR-CB in
3 patients, and mismatched sibling (2-antigen mis-
match at the HLA-DR and -DQ loci) for 1 patient.
A serologic technique was used for HLA class 1 (-A,
-B, and -C loci), and a molecular technique was used
for HLA class 2 (-DRB1 and -DQB1 loci).
GVHD Prophylaxis
GVHD prophylaxis consisted of cyclosporine A
(CsA) and methotrexate (MTX) at standard doses for
patients undergoing MRD and MMRD HSCT, and
CsA and methylprednisolone for patients undergoing
UR-CB HSCT. CsA was tapered in the absence of
GVHD after 100 days in theMRD recipients and after
180 days in UR-CB recipients.
Supportive Care
All patients were placed in a high-efficiency partic-
ulate air–filtered rooms until their absolute neutrophil
count exceeded 0.5 109/L for 3 consecutive days. In-
travenous immunoglobulin was administered every 2
weeks at a dose of 0.5 g/kg starting on day -7 before
HSCT and continuing until B cell recovery was
achieved. All blood products were irradiated and
leukocyte-filtered. All patients received acyclovir pro-
phylaxis for 28 days starting on day -3 before HSCT.
Bone marrow recovery was defined as an absolute
neutrophil count .0.5  109/L and an unsupported
platelet count .20  109/L for 3 consecutive days.
Engraftment and GVHD
Chimerism was analyzed by fluorescence in situ
hybridization in sex-mismatched donors and by vari-
able number tandem repeat in same-sex donors. In
2004, both of these techniques were supplanted by
the short tandem repeat technique. Immune reconsti-
tution was demonstrated by flow cytometric detection
of CD11/CD18 expression on lymphocyte and granu-
locyte surfaces.
GVHD (acute and chronic) was defined according
to standard criteria and confirmed by histopathologic
diagnosis when necessary [12,13]. All patients were
treated with the standard protocol and received
additional immunomodulatory therapy as needed.RESULTS
Pretransplantation Status
Fourteen HSCTs were performed in 11 patients
with the severe LAD-1 phenotype. Nine patients
were diagnosed based on typical clinical presentation
and lack of CD18 expression on neutrophils and
monocytes (\1%); the other 2 patients were diagnosed
through newborn screening based on a positive family
Table 1. Clinical Characteristics of Patients Pre-HSCT
Patient Sex
Age at Diagnosis,
Months Clinical Presentation Organisms Isolated
1 F 13 Delayed cord separation; secretory otitis media;
skin and mucous membrane ulcers/sepsis
Pseudomonas/Staphylococcus spp;
Streptococcus viridans
2 F 1.5 Skin infection and ulcers; omphilitis
3 M 16 Pneumonia; secretory otitis media;
skin infection; sepsis
Candida/Staphylococcus spp; Klebsiella
pneumoniae; Escherichia coli/Enterobacter
aerogenes; Group D enterococci;
Streptococcus viridans
4 F 9 Perianal skin infection; omphilitis Staphylococcus spp; Pseudomonas
5 M 0.25 Delayed cord separation; skin infection;
perianal abscess; pneumonia;
secretory otitis media
Group D enterococci; Pseudomonas/
Candida; Staphylococcus spp
6 F 0.25 Delayed cord separation; skin infection Staphylococcus spp/Pseudomonas;
Enterococcus faecalis; Klebsiella pneumoniae
7 M 2 Omphilitis; pneumonia; skin infection Staphylococcus spp; methicillin-resistant
Staphylococcus aureus
8 F 2 Omphilitis; respiratory syncytial
virus pneumonia
Staphylococcus spp
9 M 1 Pneumonia
10 F 1 Skin infection; omphilitis
11 F 4 Pneumonia; delayed cord separation
Biol Blood Marrow Transplant 17:1245-1249, 2011 1247Allogeneic HSCT in LAD-1history. The median age at diagnosis was 4.7 months
(range, 1-16 months). Pretransplantation clinical char-
acteristics are summarized in Table 1.
The graft sources were anMRD in 7 patients, UR-
CB in 3 patients, and anMMRD in 1 patient. Three pa-
tients (2, 5, and 9) required a secondHSCT. Patients 2
and 5 underwent the second HSCT with a graft from
the samedonor as for their firstHSCT,whereas patient
9 did so with a different UR-CB source. The median
age at HSCT was 8.8 months (range, 3-18 months).
The median CD341 stem cell–infused dose was 8.9 
106/kg (range, 4.93-13.97  106/kg) in related HSCT
and 0.28 106/kg (range, 0.04-0.56  106/kg) in UR-
CB HSCT (Table 2). The median total nucleated cell
count was 0.76  109/kg (range, 0.41-1.33  109/kg).
Engraftment and Immune Reconstitution
The median time to neutrophil recovery was 19
days (range, 13-36 days), and that to platelet recoveryTable 2. BMT Characteristics
Patient
Age at HSCT,
Months Donor
CD34/kg,
106
Conditionin
Regimen
1 17 Matched sibling 9.26 BU/CY
2 7 Haploidentical brother BU/CY
9 Haploidentical brother BU/CY
3 18 Matched sibling 13.97 BU/CY
4 11 Matched sibling 8.39 BU/CY
5 3 Matched sibling 5.13 BU/CY
9 Matched sibling 12.14 BU/CY/VP16/A
6 7 Matched sibling 4.93 BU/CY
7 8 UR-CB 0.56 BU/CY/ATG
8 3 UR-CB 0.19 BU/CY/ATG
9 6 UR-CB 0.04 BU/CY/ATG
14 UR-CB 0.34 CY/ATG/TBI
10 5 Matched sibling 9.26 BU/CY
11 6 Matched sibling 8.25 BU/CY
AIHA indicates autoimmune hemolytic anemia; AIT, autoimmune thrombocytwas 34 days (range, 14-56 days). Seven patients en-
grafted after their first HSCT and maintained stable
immune reconstitution. Patient 7 had stable donor
lymphoid cell engraftment as detected by chimerism
study and CD18 expression. He continued to demon-
strate low CD18 expression (1%) on granulocytes de-
spite undetectable myeloid cell engraftment.
As shown in Table 2, 3 patients (2, 5, and 9)
required a second HSCT because of engraftment
failure (27% failure rate). After the second HSCT,
successful engraftment was achieved in patients 5 and
9. Overall, 9 out of the 11 patients demonstrated
stable immune reconstitution, for a success rate of 82%.
On last follow-up, post-HSCT chimerism analysis
found amedian chimerism of 70% (range, 11%-100%)
for lymphocytes and 55% (range, 0%-100%) for mye-
loid cells. Post-HSCT median CD18 expression over
granulocytes and lymphocytes was 58% (range, 1%-
100%) and 61% (range, 18%-93%), respectively,g
GVHD Prophylaxis Complications/GVHD
T Cell
Depletion
CsA/MTX -
CsA/MTX -
CsA/MTX Sepsis +
CsA/MTX -
CsA/MTX -
CsA/MTX -
TG CsA/MTX Mastoidectomy with
hearing loss
-
CsA/MTX Acute grade II skin GVHD -
CsA/methylprednisolone Pneumonia, sepsis -
CsA/methylprednisolone Pneumonia, mucositis -
CsA/methylprednisolone AIHA, AIT -
CsA/methylprednisolone -
CsA/MTX Mucositis, VOD -
CsA/MTX VOD
openia; VOD, veno-occlusive disease.
Table 3. Immune Reconstitution at the Last Follow-Up
Patient Months Post-HSCT
CD18 FISH/STR
SurvivalGranulocytes Lymphocytes Myeloid Lymphoid
1 223 35 64 ND ND A/W
2 — — — — — Died
3 161 60 18 ND ND A/W
4 157 63 90 71 81 A/W
5 140 39 74 43 53 A/W
6 122 99 39 ND ND A/W
7 37 1 18 0 11 A/W
8 35 85 89 100 85 A/W
9 19 100 93 100 100 A/W
10 22 3 36 7 62 A/W
11 15 90 89 63 100 A/W
FISH indicates fluorescence in situ hybridization; STR, single tandem repeat; A/W, alive and well; ND, not done.
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months), as shown in Table 3.
GVHD
Acute grade II skin GVHD occurred in 1 patient
(patient 6), who responded well to treatment with ste-
roids and CsA. None of the patients developed chronic
GVHD.
Survival and Complications
Event-free survival was 91% for all patients, with
100% (6/6) for MRD recipients and 100% (3/3) for
UR-CB recipients. One patient (patient 2) died after
the second HSCT secondary to bacterial sepsis. Sus-
pected veno-occlusive disease occurred in two patients
(patients 10 and 11), whereas autoimmune hemolytic
anemia and autoimmune thrombocytopenia occurred
in only one patient (patient 9). No patient developed
viral disease or reactivation.0
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Figure 1. Patient 7, CD18 expression and chimerism.DISCUSSION
LAD-1 is a rare immunodeficiency disorder world-
wide; however, it seems to be more common in the
Arabian Peninsula, including Saudi Arabia. As has
been demonstrated in other types of primary immuno-
deficiencies [14-16], this higher prevalence is likely
related to the high incidence of consanguinity in
Saudi Arabia, which approaches 50% [17].
This retrospective analysis of 14 HSCTs per-
formed in 11 patients with LAD-1 is one of the largest
case series reported from a single center to date. It
clearly demonstrates that HSCT can provide a cure
for LAD-1, as has been reported previously [6-10].
Moreover, we found a 100% event-free survival and
90% stable immune reconstitution for MRD and
UR-CB HSCT recipients, with minimal toxicity.
The post-HSCT level of functional CD18 expres-
sion necessary to prevent infection has not been well
explored; however, observations from animal studiessuggest that low levels can prevent recurrent infection
[18,19]. Thomas et al. [9] reported that levels of mixed
engraftment as low as 5% may be sufficient to prevent
major infections. In agreement with this, 2 of our
patients (7 and 10) had a CD18 expression level of
1%-3%, which seemed sufficient to prevent major
infections (Figures 1 and 2). Interestingly, patient 7
continued to express very low CD18 expression on
granulocytes despite no detectable donor myeloid
cells. This indicates that close monitoring and
follow-up for such asymptomatic patients is a plausible
approach to determining the need for a secondHSCT.
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Figure 2. Patient 10, CD18 expression and chimerism.
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CB HSCT in LAD-1, our study and others suggest
that UR-CB is a promising alternative when a fully
matched donor is not available [10,11]. Three
patients (7, 8, and 9) received 4 UR-CB transplants
at ages 3, 6, 8, and 15 months. Two of these patients
successfully engrafted with full donor cell chimerism,
even though one of them (patient 9) achieved this
only after the second HSCT. The overall event-free
survival was 100%. The conditioning regimen was
well tolerated, with neither toxicity nor GVHD com-
plications seen.
Our results demonstrate a low incidence of
GVHD, likely related to the availability of fully
matched siblings in our cohort. Long-term follow-up
in all patients found a survival rate of 91% with a me-
dian follow-up of 9 years. Three patients (5, 7, and 10)
remained asymptomatic with low CD18 expression.
Further large, multicenter studies on the long-term
outcome of HSCT in LAD-1 are needed.ACKNOWLEDGMENTS
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